the standstill agreement by indicating interest in a merger. Speculation about an impending merger between Warner and
American Home Products (AHP) came to a head on November 19, 1999, when an article appeared in the Wall Street Journal
announcing an impending merger of equals between Warner and AHP valued at $58.3 billion.
The public announcement of the agreement to merge between Warner and AHP released Pfizer from the standstill
agreement. Tinged with frustration and impatience at what Pfizer saw as stalling tactics, Steere outlined in the letter the
primary reasons why the proposed combination of the two companies made sense to Warner’s shareholders. In addition to a
substantial premium over Warner’s current share price, Pfizer argued that combining the companies would result in a
veritable global powerhouse in the pharmaceutical industry. Furthermore, the firm’s product lines are highly complementary,
including Warner’s over-the-counter drug presence and substantial pipeline of new drugs and Pfizer’s powerful global
marketing and sales infrastructure. Steere also argued that the combined companies could generate annual cost savings of at
least $1.2 billion annually within 1 year following the completion of the merger. These savings would come from centralizing
computer systems and research and development (R&D) activities, consolidating more than 100 manufacturing facilities, and
combining two headquarters and multiple sales and administrative offices in 30 countries. Pfizer also believed that the two
companies’ cultures were highly complementary.
In addition to the letter from Steere to de Vink, on November 4, 1999, Pfizer announced that it had commenced a legal
action in the Delaware Court of Chancery against Warner, Warner’s directors, and AHP. The action sought to enjoin the
approximately $2 billion termination fee and the stock option granted by Warner-Lambert to AHP to acquire 14.9% of
Warner’s common stock valued at $83.81 per share as part of their merger agreement. The lawsuit charged that the
termination fee and stock options were excessively onerous and were not in the best interests of the Warner shareholders
because they would discourage potential takeover attempts.
On November 5, 1999, Warner explicitly rejected Pfizer’s proposal in a press release and reaffirmed its commitment to its
announced business combination with AHP. On November 9, 1999, de Vink sent a letter to the Pfizer board in which he
expressed Warner’s disappointment at what he perceived to be Pfizer’s efforts to take over Warner as well as Pfizer’s lawsuit
against the firm. In the letter, he stated Warner-Lambert’s belief that the litigation was not in the best interest of either
company’s stockholders, especially in light of their co-promotion of Lipitor, and it was causing uncertainty in the financial
markets. Not only did Warner reject the Pfizer bid, but it also threatened to cancel the companies’ partnership to market
Lipitor.
Pfizer responded by exploiting a weakness in the Warner Lambert takeover defenses by utilizing a consent solicitation
process that allows shareholders to change the board without waiting months for a shareholders’ meeting. Pfizer also
challenged in court two provisions in the contract with AHP on the grounds that they were not in the best interests of the
Warner Lambert shareholders because they would discourage other bidders. Pfizer’s offers for Warner Lambert were
contingent on the removal of these provisions. On November 12, 1999, Steere sent a letter to de Vink and the Warner board
indicating his deep disappointment as a result of their refusal to consider what Pfizer believes is a superior offer to Warner.
He also reiterated his firm’s resolve in completing a merger with Warner. Not hearing anything from Warner management,
Pfizer decided to go straight to the Warner shareholders on November 15, 1999, in an attempt to change the composition of
the board and to get the board to remove the poison pill and break-up fee.
In the mid-November proxy statement sent to Warner shareholders, Pfizer argued that the current Warner Lambert board
has approved a merger agreement with American Home, which provides 30% less current value to the Warner-Lambert
stockholders than the Pfizer merger proposal. Moreover, Warner shareholders would benefit more in the long run in a merger
with Pfizer, because the resulting firm would be operationally and financially stronger than a merger created with AHP.
Pfizer also argued that its international marketing strength is superior in the view of most industry analysts to that of
American Home and will greatly enhance Warner-Lambert’s foreign sales efforts. Pfizer stated that Warner Lambert was not
acting in the best interests of its shareholders by refusing to even grant Pfizer permission to make a proposal. Pfizer also
alleged that Warner Lambert is violating its fiduciary responsibilities by approving the merger agreement with American
Home in which AHP is entitled to a termination fee of approximately $2 billion.
Pressure intensified from all quarters including such major shareholders as the California Public Employees Retirement
System and the New York City Retirement Fund. After 3 stormy months, Warner Lambert agreed on February 8, 2000, to be
acquired by Pfizer for $92.5 billion, forming the world’s second largest pharmaceutical firm. Although they were able to
have the Warner poison pill overturned in court as being an unreasonable defense, Pfizer was unsuccessful in eliminating the